AmpliPhi raises $7m in placement
Bacteriophage-based treatment company AmpliPhi Biosciences has completed a $7 million private placement to fund its development activities.
The financing round was led by established life sciences investors RA Capital Management and Third Security. BioScience Managers also participated.
“We are very pleased to have the support of these outstanding life science investors,” AmpliPhi CEO Philip J Young said.
As part of its investment, Third Security will appoint managing director Julian P Kirk to the AmpliPhi board. Existing AmpliPhi board members Dr Caroline Williams and Tony Gellert have meanwhile stepped down.
US-based AmpliPhi last year merged with Australia’s Special Phage Services. Gellert had joined the board as a result of this merger.
The combined company is focused on developing antibacterial treatments for antibiotic-resistant bacterial infections. Its lead program centres on treatments for chronic and acute lung infections.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
